Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Blocking anaplerotic entry of glutamine into the TCA cycle sensitizes K-Ras mutant cancer cells to cytotoxic drugs.

Oncogene - 14 May 2015

Saqcena M, Mukhopadhyay S, Hosny C, Alhamed A, Chatterjee A, Foster D A

Abstract excerpt

Cancer cells undergo a metabolic transformation that allows for increased anabolic demands, wherein glycolytic and tricarboxylic acid (TCA) cycle intermediates are shunted away for the synthesis of biological molecules required for cell growth and division. One of the key shunts is the exit of citrate from the mitochondria and the TCA cycle for the generation of cytosolic acetyl-coenzyme A that can be used for...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antimetabolites, Antineoplastic
Share to Antineoplastic Agents, Phytogenic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Capecitabine

Share to Cell Cycle Checkpoints

Share to Citric Acid Cycle

Share to Cytotoxins

Share to Deoxycytidine

Share to Paclitaxel

Source

Open in PubMed Open full text

Identifiers

PMID: 25023699
DOI: 10.1038/onc.2014.207
PMCID: PMC4418945

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Blocking anaplerotic entry of glutamine into the TCA cycle sensitizes K-Ras mutant cancer cells to cytotoxic drugs.PMID 25023699Read ↗

Dual targeting of glutamine metabolism and lysosomal function in eliminating drug-tolerant KRAS-mutant cancer cells.Semantic proximity Read ↗

Apoptotic effects of high-dose rapamycin occur in S-phase of the cell cycleSemantic proximity Read ↗

Glutamine deprivation counteracts hypoxia-induced chemoresistanceSemantic proximity Read ↗

Role and therapeutic targeting of glutamine metabolism in non‑small cell lung cancer (Review)Semantic proximity Read ↗

Glucose-independent Acetate Metabolism Promotes Melanoma Cell Survival and Tumor Growth.Semantic proximity Read ↗

Colorectal cancers utilize glutamine as an anaplerotic substrate of the TCA cycle in vivo.Semantic proximity Read ↗

Metabolic vulnerability of cisplatin‐resistant cancersSemantic proximity Read ↗

Supraphysiological glutamine as a means of depleting intracellular amino acids to enhance pancreatic cancer chemosensitivitySemantic proximity Read ↗

Oncogenic PIK3CA mutations reprogram glutamine metabolism in colorectal cancer.Semantic proximity Read ↗

Sphingolipid-based drugs selectively kill cancer cells by down-regulating nutrient transporter proteinsSemantic proximity Read ↗

An Asp to Strike Out Cancer? Therapeutic Possibilities Arising from Aspartate’s Emerging Roles in Cell Proliferation and SurvivalSemantic proximity Read ↗

Metformin Antagonizes Cancer Cell Proliferation by Suppressing Mitochondrial-Dependent Biosynthesis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.